Site-Specific Factor 22
Multigene Signature Method
Notes
**Note 1:** Multigene signatures or classifiers are assays of a panel of genes from a tumor specimen, intended to provide a quantitative assessment of the likelihood of response to chemotherapy and to evaluate prognosis or distant recurrence. * Oncotype DX and MammaPrint (also called MammoPrint) are two commercially available genomic tests **Note 2:** Code the type of test performed. The same test should be used to record information in **Site-Specific Factor 22, Multigene Signature Method** and **Site-Specific Factor 23, Multigene Signature Results**. **Note 3:** This information may not be available at diagnosis and may require follow-up with the physician.Default
999NAACCR Item
NAACCR #2876Metadata
None| Code | Description |
|---|---|
| 010 | Oncotype DX |
| 020 | MammaPrint (MammoPrint) |
| 030 | Other |
| 040 | Test performed, type of test unknown |
| 988 | Not applicable: Information not collected for this case |
| 998 | Test not done (test not ordered and not performed) |
| 999 | Unknown or no information Not documented in patient record |